Q-omics provides the consensus-scored HCG18 profile across patient tissues and cancer cell-line models. HCG18 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HCG18 is differentially expressed in 14, with the highest sampling consensus in LUAD. Additionally, HCG18 RNA expression shows 21,091 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, LUAD, and ACC as cancer lineages where HCG18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCG18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCG18 survival associations across molecular data types. HCG18 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCG18 RNA expression–survival associations across cancer types. High HCG18 expression shows unfavorable associations in MESO, ACC and LIHC, but favorable associations in READ, THYM and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for HCG18 RNA expression.
This table summarizes HCG18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HCG18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCG18 shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD, COAD, LIHC and HNSC. The LUAD box plot shows higher HCG18 RNA expression in tumor versus normal tissue (log2 FC = +0.639, t-test p < 0.001).
This table shows molecular features associated with HCG18 in patient tissues and cancer cell lines. In patient samples, HCG18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HCG18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in NCI60_ALL.
